Cvrx Inc (CVRX) Stock Price, Quote & News

Company Profile

CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular sy...

Industry: Medical Devices

Sector: Healthcare

Phone: 763 416 2840

Fax: 763 416 2841

Website: www.cvrx.com

Address:

9201 West Broadway Avenue, Suite 650, Minneapolis, United States

Felaw Mar. 20 at 4:37 PM

$CVRX need to break 9.02

0 · Reply

BioGem Mar. 15 at 8:46 PM

$CVRX I am adding to my short in the high $7's. All what I said previously stays true, and the short interest has rapidly gone up since then. This will tank big after the Q1 26 losses are posted. Insider buying does not change the poor fundamentals.

1 · Reply

MedDevice Mar. 11 at 9:26 PM

$CVRX THT late breaker update scheduled for 3/12 cancelled and X posts deleted by CVRx. If the late breaking info is worthy of a press release to Wall Street, aren’t the results as well?

1 · Reply

MedDevice Mar. 10 at 6:49 PM

$CVRX top line Q1 revenue, 255 active centers and a 31K asp = 1.86 implants per active center. Q1 2024 had 1.8 per active center. Where's the growth in this growth stock?

0 · Reply

MedDevice Feb. 28 at 10:30 PM

$CVRX 6 associate territory manager positions posted. Analysts and investors need clarification on this role and if "enhanced" talent is being recruited for these positions. A quick glance at profiles of those with this title appear to be nurses and others with limited to no selling experience. There are 5 territory manager positions posted, 3 in large Florida cities, 1 in San Diego and 1 in Detroit. Expansion roles? More "enhancement" to the sales organization? Turnover? Sales director role for the Northeast posted as well. The results havent supported growth being the reason for these roles. Until proven otherwise, must model other reasons as management has communicated the enhancements are complete.

2 · Reply

MedDevice Feb. 26 at 9:29 PM

$CVRX highest daily trading volume in a year. total volume approaching 9m for February.

0 · Reply

StockScanners Feb. 24 at 4:35 AM

$CVRX reached 7.22

0 · Reply

davidbo Feb. 23 at 4:43 PM

$CVRX looks like a board member just bought 46500 shares on the open market, we shall see.

0 · Reply

BillionerOfKing Feb. 22 at 10:43 PM

$CVRX Current Stock Price: $6.12 Contracts to trade: $5.0 CVRX Mar 20 2026 Call Entry: $0.80 Exit: $1.01 ROI: 26% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

SuperGreenToday Feb. 21 at 12:05 PM

$CVRX Share Price: $6.12 Contract Selected: Dec 18, 2026 $5 Calls Buy Zone: $1.78 – $2.21 Target Zone: $3.06 – $3.74 Potential Upside: 62% ROI Time to Expiration: 299 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

CVRx Announces Late-Breaking Data and Scientific Presentations Highlighting Barostim Outcomes at the THT 2026 Annual Meeting

Feb 12, 2026, 10:14 PM EST - 5 weeks ago

CVRx, Inc. (CVRX) Q4 2025 Earnings Call Transcript

Jan 29, 2026, 4:10 PM EST - 7 weeks ago

CVRx to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call on February 12, 2026

Jan 23, 2026, 12:33 PM EST - 2 months ago

CVRx Kicks Off One Of The Largest Heart Device Trials In History

Jan 22, 2026, 4:05 PM EST - 2 months ago

CVRx Announces Initiation of BENEFIT-HF, a Landmark Heart Failure Trial Evaluating Barostim in Significantly Expanded Population

Jan 14, 2026, 9:15 PM EST - 2 months ago

CVRx, Inc. (CVRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:00 AM EST - 2 months ago

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2025 Financial Results and Issues Fiscal 2026 Guidance

Jan 6, 2026, 8:30 AM EST - 2 months ago

CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy

Dec 22, 2025, 8:30 AM EST - 3 months ago

CVRx to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 19, 2025, 8:30 AM EST - 4 months ago

CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

Nov 5, 2025, 10:51 PM EST - 4 months ago

CVRx, Inc. (CVRX) Q3 2025 Earnings Call Transcript

Oct 22, 2025, 4:30 PM EDT - 5 months ago

CVRx to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call on Nov. 5, 2025

Aug 4, 2025, 7:27 PM EDT - 8 months ago

CVRx, Inc. (CVRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 4:05 PM EDT - 8 months ago

CVRx Reports Second Quarter 2025 Financial and Operating Results

Jul 29, 2025, 8:30 AM EDT - 8 months ago

CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 7:30 AM EDT - 8 months ago

CVRx Announces Positive News on Outpatient Payment for Barostim

Jul 2, 2025, 4:02 AM EDT - 9 months ago

CVRx: Sell-Off Ignores Its True Potential

May 28, 2025, 4:30 PM EDT - 10 months ago

CVRx to Present at the William Blair 45th Annual Growth Stock Conference

May 10, 2025, 3:51 PM EDT - 11 months ago

CVRx, Inc. (CVRX) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 4:30 PM EDT - 11 months ago

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

Apr 9, 2025, 8:45 AM EDT - 1 year ago

CVRx Inc: Overreaction Creates Buying Opportunity

Apr 8, 2025, 8:35 AM EDT - 1 year ago

Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

GBX RPM

Apr 7, 2025, 4:05 PM EDT - 1 year ago

CVRx Reports Preliminary First Quarter 2025 Financial Results

Feb 12, 2025, 2:45 PM EST - 1 year ago

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

Feb 4, 2025, 11:00 PM EST - 1 year ago

CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript

Feb 4, 2025, 4:05 PM EST - 1 year ago

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Jan 21, 2025, 4:30 PM EST - 1 year ago

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

Dec 23, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 20, 2024, 4:30 PM EST - 1 year ago

CVRx to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 9:04 PM EST - 1 year ago

CVRx: Impressive Top-Line Growth Seems Priced In

Oct 29, 2024, 10:38 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript

Oct 18, 2024, 2:08 PM EDT - 1 year ago

CVRx announces new CPT® Category I codes for Barostim

Oct 15, 2024, 4:30 PM EDT - 1 year ago

CVRx to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call on October 29, 2024

Sep 3, 2024, 8:30 AM EDT - 1 year ago

CVRx Announces Appointment of Two New Board Members

Aug 19, 2024, 4:00 PM EDT - 1 year ago

CVRx, Inc. (CVRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 19, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Investigating CVRx Inc For Securities Fraud And Urging Investors To Join

Aug 18, 2024, 11:00 AM EDT - 1 year ago

The Schall Law Firm Is Seeking CVRx Inc Shareholders To Join Fraud Investigation

Aug 17, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Shareholders Can Join Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 1 year ago

CVRx Inc Investors Encouraged To Participate In Fraud Inquiry With The Schall Law Firm

Felaw Mar. 20 at 4:37 PM

$CVRX need to break 9.02

0 · Reply

BioGem Mar. 15 at 8:46 PM

1 · Reply

MedDevice Mar. 11 at 9:26 PM

$CVRX THT late breaker update scheduled for 3/12 cancelled and X posts deleted by CVRx. If the late breaking info is worthy of a press release to Wall Street, aren’t the results as well?

1 · Reply

MedDevice Mar. 10 at 6:49 PM

$CVRX top line Q1 revenue, 255 active centers and a 31K asp = 1.86 implants per active center. Q1 2024 had 1.8 per active center. Where's the growth in this growth stock?

0 · Reply

MedDevice Feb. 28 at 10:30 PM

2 · Reply

MedDevice Feb. 26 at 9:29 PM

$CVRX highest daily trading volume in a year. total volume approaching 9m for February.

0 · Reply

StockScanners Feb. 24 at 4:35 AM

$CVRX reached 7.22

0 · Reply

davidbo Feb. 23 at 4:43 PM

$CVRX looks like a board member just bought 46500 shares on the open market, we shall see.

0 · Reply

BillionerOfKing Feb. 22 at 10:43 PM

0 · Reply

SuperGreenToday Feb. 21 at 12:05 PM

0 · Reply

StockScanners Feb. 21 at 6:10 AM

$CVRX keep watch if this holds above 5.99

0 · Reply

topstockalerts Feb. 20 at 4:39 PM

$CVRX Not a bad session at all for momentum traders 🙌. Price moved cleanly higher. Buyers stayed in control.

0 · Reply

OfficialStocktwitsUser Feb. 20 at 4:10 PM

$CVRX RSI: 36.76, MACD: -0.5221 Vol: 0.88, MA20: 6.39, MA50: 7.00 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

MedDevice Feb. 20 at 1:31 PM

$CVRX https://www.businesswire.com/news/home/20260219239130/en/Securities-Fraud-Investigation-Into-CVRx-Inc.-CVRX-Announced-Shareholders-Who-Lost-Money-Urged-To-Contact-Glancy-Prongay-Wolke-Rotter-LLP-a-Leading-Securities-Fraud-Law-Firm?utm_campaign=shareaholic&utm_medium=copy_link&utm_source=bookmark

0 · Reply

TwoToesTrading Feb. 18 at 10:27 PM

$LXRX $NTWK $CVRX $DLHC $STEX Some insiders today

1 · Reply

MITornado Feb. 17 at 8:30 PM

$CVRX are we in a better position or worse position than we were a year ago?

1 · Reply

crumpy1 Feb. 17 at 5:34 PM

$CVRX ATM is working

0 · Reply

MarketEfficiency Feb. 17 at 2:36 PM

$CVRX CVRx neuromodulation for heart failure; requires clinical proof for adoption.

1 · Reply

MedDevice Feb. 17 at 1:29 AM

$CVRX Target implants: 3 per center × 252 centers = 756 total U.S. implants. Overall weighted conversion rate (prescription → implant): 60.15% (based on payer mix):40% Medicare Advantage at 46% conversion 40% Traditional Medicare at 100% 15% Commercial at 10% 5% Other at 5% Prescriptions required: 756 ÷ 0.6015 ≈ 1,257 Per center: 1,257 ÷ 252 ≈ 4.99 (or roughly 5 prescriptions per center to achieve the 3-implant goal). This means each active center would need to generate ~5 new Barostim prescriptions in the quarter, with ~60% of those ultimately converting to implants (yielding the target 3 implants per center). Just some rough math based on a 46% 30 day approval rate for Medicare Advantage(reported by leadership) and no prior authorization needed for Medicare, as reported by CVRx. Assumes a much lower conversion rate for commercial and Medicaid, as would be expected. Seems very achievable, even without the "flywheel" needed with the enhanced salesforce.

0 · Reply

d_risk Feb. 16 at 12:31 AM

$CVRX - CVRx Inc - 10K - Updated Risk Factors CVRx’s 2026 10-K ramps up risks around Barostim commercialization and growth: tougher U.S. sales hiring and hospital contracting, heavier dependence on physician adoption vs. larger rivals, fragile single-site and multi-supplier manufacturing, expanded global and macro/geopolitical pressures, leadership turnover and cybersecurity threats, more granular IP/patent and trade secret exposure, evolving AI and regulatory regimes, and heightened reimbursement and clinical trial uncertainties. #MedicalDevices #BarostimCommercialization #HealthcareAdoptionRisk #ManufacturingVulnerabilities #RegulatoryChallenges 🟢 Added 🟠 Removed https://d-risk.ai/CVRX/10-K/2026-02-13

0 · Reply

txandco Feb. 13 at 6:11 PM

$CVRX $2's make sense, load down there

0 · Reply

Market Cap	228.65M
Revenue (ttm)	56.65M
Net Income (ttm)	-53.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-94.10%
Debt to Equity Ratio	1.26

Volume	235,500
Avg Vol	385,274
Day's Range	N/A - N/A
Shares Out	26.31M
Stochastic %K	82%
Beta	1.28
Analysts	Strong Sell
Price Target	$11.17